Introduction
============

Hemorrhage is a normal physiologic response to a tissue lesion involving the vascular system, and can be caused by a topical or systemic medical or surgical intervention.[@b1-vhrm-10-569] The process of hemostasis is triggered when there is a leakage from the vascular bed and is followed by the process of coagulation, whereby a number of factors lead to formation of a clot which subsequently undergoes lysis via fibrinolysis.[@b2-vhrm-10-569],[@b3-vhrm-10-569] During bleeding, mechanical hemostasis can be achieved using traditional methods, such as manual pressure or tourniquets, compressive bandages, ligatures, sutures, clippings, or electrocautery by means of monopolar or bipolar electroscalpels.[@b4-vhrm-10-569]

Newer systems for vascular synthesis and coagulation, however, use a combination of pressure (through the handpiece-forceps) and radiofrequency applied to the target tissues.[@b5-vhrm-10-569] Thus, hemostasis does not depend on thrombus formation in the proximal vessel, but is the result of fusion of collagen and elastin in the intimal part of the vessel, which creates permanent scarring.[@b6-vhrm-10-569] Broadly, these systems are divided in three categories, ie, hemostatic dressings, surgical sealants, and blood-derived local hemostatic agents.

Hemostatic dressings are medical devices that can be derived from plants (polysaccharides, cellulose-derived products), animals (collagen and gelatin), or minerals (zeolite, only removable surgically). Their mechanism of action is chemical and/or mechanical, and they promote platelet aggregation on the surface of the wound/cut, creating a substrate for the coagulation cascade. Surgical sealants are also medical devices and can be of synthetic or semisynthetic origin. In the presence of water, the sealant is polymerized and interacts with the coagulation cascade by an exclusively mechanical action.[@b3-vhrm-10-569] The introduction of local hemostatic products identified as topical drugs of human or animal origin is more recent.[@b7-vhrm-10-569],[@b8-vhrm-10-569] These products (eg, Artiss^®^ \[Baxter International Inc., Deerfield, IL, USA\], Beriplast^®^ \[CSL Behring, King of Prussia, PA, USA\], Evicel^®^ \[OMRIX Biopharmaceuticals Ltd, Nes-Ziona, Israel\], Quixil^®^ \[OMRIX Biopharmaceuticals Ltd\] TachoSil^®^ \[Takeda Austria GmbH, Linz, Austria\], and Tisseel^®^ \[Baxter International Inc.\]) have two mechanisms of action, ie, they either work on the coagulation cascade with a metabolic hemostatic action or have a mechanical action as adhesive hemostatic agents.

These different product categories sometimes have the same clinical indications, ie, some facilitate hemostasis while others facilitate hemostasis, promote sealing, and support sutures.[@b3-vhrm-10-569] TachoSil, for example, is an equine-derived collagen sponge coated on one side with human fibrinogen and human thrombin. It is indicated as supportive treatment in adults undergoing surgery to improve hemostasis, promote tissue sealing, and support suturing in vascular surgery where standard techniques are inadequate.[@b7-vhrm-10-569],[@b8-vhrm-10-569] Unlike other drugs, TachoSil does not have special storage requirements (temperature below 25°C) and is ready for use.

The studies reported in the literature regarding the efficacy of these new products are often flawed by methodological errors and not rigorously conducted.[@b9-vhrm-10-569] In general, the studies available are not controlled and have been carried out in a limited number of surgical areas, so although these products are very widely used in a number of scenarios in clinical practice, their use is generally off-label. Research and evaluation of their potential economic impact on health care systems is even more limited, which makes it difficult for decision-makers (ie, physicians and pharmacists) to make cost-effective choices in a contest of increasing sustainability of expenditure.

Materials and methods
=====================

The aim of this review was to analyze the international scientific literature relating to the use of TachoSil in hemostasis and as a surgical sealant, from the point of view of its economic impact. We therefore carried out a systematic review of the PubMed literature up to November 2013,[@b10-vhrm-10-569] and reviewed economic evaluations comparing one or more alternatives in terms of costs and/or consequences for health care systems.[@b9-vhrm-10-569],[@b11-vhrm-10-569] The scientific papers were screened and selected based on the following inclusion criteria: clinical and economic evaluation of cost of treatment alone, cost-effectiveness, cost-utility, cost-benefit, and publication in English. Abstracts and posters were felt to lack sufficient information and therefore were not considered for inclusion. The key search terms used were "TachoSil" and "cost(s)", "economic(s)", "pharmacoeconomics", "outcome research", "topical hemostatic agents", "fibrinogen", "thrombin", "hemostatic agents", "randomized clinical trial", and "surgical hemostasis". Papers were selected if they contained clinical data showing a clear impact on use of resources by health care system (National Health Service \[NHS\], health care funds or insurance), if TachoSil was compared with other options (ie, standard suturing techniques, medical devices, surgical sealants, other hemostatic products) to improve postoperative hemostasis, and if the consequences for length of hospital stay and postoperative complications were reported.

Results
=======

The results of this systematic analysis are shown in [Figure 1](#f1-vhrm-10-569){ref-type="fig"}. Of 358 potential papers identified, 334 were excluded because they were not economic evaluations (n=143), included comparisons of drugs other than those considered in this review (n=115), or were published as case reports (n=8).

Twenty-four scientific papers were identified for inclusion in the study, 13 of which (54%) were randomized controlled trials and nine (37%) were prospective cohort studies. The studies identified included a total of 2,116 patients, 1,055 of whom were treated with TachoSil. According to our selection criteria, the papers were grouped according to the following outcomes: decrease in time to hemostasis, reduction in length of hospital stay, and decrease in postoperative complications.[@b10-vhrm-10-569]

Impact on time to hemostasis
----------------------------

Six of the selected papers were randomized controlled trials in patients undergoing hepatic, cardiac, or renal surgery.[@b12-vhrm-10-569]--[@b17-vhrm-10-569] Time to hemostasis with TachoSil was less (1--4 minutes) than that using other techniques. In patients undergoing cardiac surgery, hemostasis was reached in 3 minutes in 75% of cases using TachoSil versus 33% with other techniques.[@b14-vhrm-10-569],[@b15-vhrm-10-569] In total, 609 patients were included, 295 of whom were treated with TachoSil. The differences in time to hemostasis were statistically significant in five of the six papers[@b13-vhrm-10-569]--[@b17-vhrm-10-569] ([Table 1](#t1-vhrm-10-569){ref-type="table"}).

Change in length of hospital stay
---------------------------------

Length of hospital stay was reported by 15 of the selected papers (62% of the total number of studies screened), which were carried out in patients undergoing pulmonary, hepatic, kidney, cardiac, or gastric surgery. Seven studies (46%) were randomized controlled trials[@b18-vhrm-10-569]--[@b24-vhrm-10-569] and eight were prospective cohort studies.[@b25-vhrm-10-569]--[@b32-vhrm-10-569] These studies included 1,426 patients, 723 of whom were treated with TachoSil ([Table 2](#t2-vhrm-10-569){ref-type="table"}). A decrease in the length of postoperative hospital stay (by 2.01--3.58 days) was found for patients treated with TachoSil when compared with those treated using standard techniques. It is interesting to note that the decrease in length of hospital stay was greater in TachoSil-treated patients undergoing gastric or hepatic surgery, who showed a mean reduction in hospital stay of 3.58 and 2.33 days, respectively. Eight (53%) of the 15 studies showed a statistically significant difference in favour of TachoSil. Further, two randomized controlled trials showed that use of TachoSil in pulmonary surgery generated savings in the range of 98.00--205.50 Euros per patient when compared with standard techniques.[@b22-vhrm-10-569],[@b23-vhrm-10-569]

Decrease in postoperative complications
---------------------------------------

Reduction in postoperative complications was assessed in 15 studies carried out in patients undergoing pulmonary, hepatic, kidney, cardiac, or gastric surgery. Eight studies (53%) were randomized controlled trials[@b12-vhrm-10-569],[@b18-vhrm-10-569],[@b19-vhrm-10-569],[@b21-vhrm-10-569]--[@b24-vhrm-10-569],[@b33-vhrm-10-569] and six were prospective cohort studies.[@b28-vhrm-10-569]--[@b31-vhrm-10-569],[@b34-vhrm-10-569],[@b35-vhrm-10-569] These studies included 1,470 patients, 738 of whom were treated with TachoSil ([Table 3](#t3-vhrm-10-569){ref-type="table"}). Postoperative complications included air leaks (for lung surgery), intra- abdominal infections, asymptomatic lymphocele, pericardial complications, postoperative fistulas, and others.

Air leaks are common after pulmonary surgery, and can result in serious complications, such as empyema and a protracted hospital stay.[@b36-vhrm-10-569] Air leaks were reported to occur in up to 58% of lobectomy procedures, depending on the surgical technique used.[@b37-vhrm-10-569] Our review identified a 9%--45% decrease in air leaks in five studies (four of which were randomized) using TachoSil when compared with standard techniques.[@b18-vhrm-10-569],[@b21-vhrm-10-569]--[@b23-vhrm-10-569],[@b30-vhrm-10-569]

The literature screened showed that TachoSil plays a role in decreasing intraoperative complications and postoperative air leaks, in addition to other postoperative complications ([Table 3](#t3-vhrm-10-569){ref-type="table"}). It is important to keep in mind that a decrease in complications translates into a reduction in length of hospital stay ([Table 2](#t2-vhrm-10-569){ref-type="table"}). In 13 of the 15 papers we identified, TachoSil achieved a statistically significant reduction in the number of postoperative complications when compared with standard techniques.

Discussion
==========

In the current health care scenario of increasing costs, evaluation of the potential benefits of any given treatment should take into account its cost-effectiveness in comparison with standard treatments as well as its medium-term and long-term effects on both clinical outcome and total health care costs.[@b38-vhrm-10-569] Systematic literature reviews identify, assess, and summarize the results of individual studies, and make these results available and more accessible to health care decision-makers.[@b9-vhrm-10-569] This review of the literature shows the relevance of TachoSil as a supportive treatment in surgery to improve hemostasis and promote tissue sealing when standard techniques are inadequate. Our findings are strengthened by the high number of studies screened (n=24), 54% of which were randomized controlled trials and included a total of 2,116 patients. A statistically significant difference in favor of TachoSil was found in eight of 15 (53%) screened studies for decreased length of hospital stay and in 13 of 15 (87%) for reduction in postoperative complications, with a consequent decrease in hospital expenditure. Similar results were reported in a previous systematic review of the literature addressing the economic impact of TachoSil,[@b10-vhrm-10-569] but the number of papers we reviewed (n=24) was much higher than that identified in the earlier review in 2011 (n=15). Our review highlights further the role of TachoSil in reducing hospital costs and postoperative complications in a larger number of patients.

Moreover, as confirmed by other systematic reviews, TachoSil also helps to decrease the number of blood transfusions required.[@b7-vhrm-10-569] From an economic point of view, the 4-minute decrease in time to hemostasis observed for TachoSil with respect to standard techniques translates into reduced theater time and less staff requirements per treated patient. Finally, TachoSil is very easy to store (room temperature, 3-year shelf-life) and use (no requirement for thawing). This makes it a reference product for comparison with other hemostatic drugs, such as Tisseel, Quixil, Evicel, or Artiss.[@b3-vhrm-10-569]

This review has some limitations. Not all the selected studies were randomized controlled trials (54%) and the economic endpoint was generally secondary in the design of these studies. Moreover, no pharmacoeconomic simulation models were included. Such pharmacoeconomic studies would have helped decision-makers by highlighting the key elements for choice of the best topical hemostatic agent and surgical sealant and would also help clinicians in outlining prospective economic evaluations and in correctly quantifying the costs of treatment.[@b39-vhrm-10-569]

Some health economists have criticized the value of systematic reviews for economic evaluations in the health care setting.[@b40-vhrm-10-569] When conducting a systematic search, it is possible that not all relevant studies are identified. On the other hand, as discussed by other researchers,[@b38-vhrm-10-569],[@b40-vhrm-10-569] search terms like "economic evaluation", "economics", and "cost" in studies can lead to identification of a number of studies which are potentially irrelevant to a systematic review.

Moreover, differences in study design and methodology make it extremely difficult to synthetize the studies identified in a coherent set. However, methods have now been developed to guide such reviews,[@b9-vhrm-10-569],[@b41-vhrm-10-569] and a large number of systematic reviews have been conducted in various therapeutic areas, including ischemic stroke,[@b42-vhrm-10-569] chronic obstructive pulmonary disease,[@b43-vhrm-10-569] and hepatitis B and C.[@b44-vhrm-10-569],[@b45-vhrm-10-569] In the future, our ability to identify which topical hemostatic agent or surgical sealant should be used in a particular patient will depend increasingly on the quality of information available regarding prevention of postoperative complications in clinical practice and, indirectly, on the possibility of optimizing the use of hospital services. High-quality information would be necessary to optimize total health expenditure and simultaneously improve patient quality of life.
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###### 

Time to hemostasis reduction: TachoSil versus other standard techniques

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Year   Countries                                Design                      Surgery   Sealing agents       Patient no   Time to hemostasis    Statistical difference (*P*-value)
  ---------------------------------- ------ ---------------------------------------- --------------------------- --------- -------------------- ------------ --------------------- ------------------------------------
  Kakaei et al[@b12-vhrm-10-569]     2013   Iran                                     Randomized clinical trial   Hepatic   TachoSil\            15\          3.0 min\              *P*=0.43
                                                                                                                           Surgicel\            15\          3.2 min\              
                                                                                                                           Glubran 2            15           2.6 min               

  Fischer et al[@b13-vhrm-10-569]    2011   Germany, Austria, Denmark                Randomized clinical trial   Hepatic   TachoSil\            60\          3.6 min\              *P*=0.001
                                                                                                                           Argon coagulator     59           5.0 min               

  Bajardi et al[@b14-vhrm-10-569]    2009   Italy                                    Randomized clinical trial   Cardiac   TachoSil\            10\          264±127.1 sec\        *P*=0.02
                                                                                                                           Standard technique   10           408±159.5 sec         

  Maisano et al[@b15-vhrm-10-569]    2009   Germany, Denmark, Spain, France, Italy   Randomized clinical trial   Cardiac   TachoSil\            59\          After 3.6 min: 75%\   *P*\<0.0001
                                                                                                                           Standard technique   60           After 3 min: 33%      

  Siemer et al[@b16-vhrm-10-569]     2007   Germany, Austria, Belgium                Randomized clinical trial   Renal     TachoSil\            92\          5.3 min\              *P*\<0.0001
                                                                                                                           Standard technique   93           9.5 min               

  Frilling et al[@b17-vhrm-10-569]   2005   Germany                                  Randomized clinical trial   Hepatic   TachoSil\            59\          3.9 min\              *P*=0.0007
                                                                                                                           Argon coagulator     62           6.3 min               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** min, minutes; sec, seconds.

###### 

Hospital stay length reduction: TachoSil versus standard technique

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                               Year   Countries                                    Design                      Surgery                 Sealing agents       Patient no   Hospital stay (days)   Statistical difference (*P*-value)
  ------------------------------------ ------ -------------------------------------------- --------------------------- ----------------------- -------------------- ------------ ---------------------- ------------------------------------
  Filosso et al[@b18-vhrm-10-569]      2013   Italy                                        Randomized clinical trial   Lung                    TachoSil\            13\          6.9\                   *P*\<0.001
                                                                                                                                               Standard technique   11           9.5                    

  Cormio et al[@b24-vhrm-10-569]       2012   Italy                                        Randomized clinical trial   Kidney                  TachoSil\            50\          2.75 (±1.78)\          *P*\<0.0001
                                                                                                                                               Standard technique   50           5.15 (±1.74)           

  Montorsi et al[@b19-vhrm-10-569]     2012   Italy                                        Randomized clinical trial   Pancreatic              TachoSil\            145\         7\                     ns
                                                                                                                                               Standard technique   130          10                     

  Pilone et al[@b20-vhrm-10-569]       2012   Italy                                        Randomized clinical trial   Gastric                 TachoSil\            15\          6.5\                   ns
                                                                                                                                               Standard technique   15           7                      

  De Rosa et al[@b25-vhrm-10-569]      2011   Italy                                        Prospective cohort          Hepatic                 TachoSil\            15\          6.7\                   ns
                                                                                                                                               Standard technique   10           8.3                    

  Pavlik et al[@b26-vhrm-10-569]       2011   Norway                                       Retrospective cohort        Pancreatic resection    TachoSil\            73\          5 (2--16)\             ns
                                                                                                                                               Standard technique   48           5.5 (2--35)            

  De Stefano et al[@b27-vhrm-10-569]   2011   Italy                                        Prospective cohort          Gastric                 TachoSil\            24\          7.2\                   ns
                                                                                                                                               Standard technique   39           9.3                    

  Briceno et al[@b28-vhrm-10-569]      2010   Spain                                        Prospective cohort          Hepatic                 TachoSil\            57\          9.6±5.1\               *P*=0.03
                                                                                                                                               Standard technique   58           12.6±6.7               

  Marta et al[@b21-vhrm-10-569]        2010   Germany, Austria, Denamark, Hungary, Italy   Randomized clinical trial   Lung                    TachoSil\            148\         8 (1--36)\             *P*=0.35
                                                                                                                                               Standard technique   151          9 (4--28)              

  Padillo et al[@b29-vhrm-10-569]      2010   Spain                                        Prospective cohort          Pancreatic transplant   TachoSil\            34\          22.8±11.1\             *P*=0.03
                                                                                                                                               Standard technique   34           34.6±11.3              

  Rena et al[@b30-vhrm-10-569]         2009   Italy                                        Prospective cohort          Lung                    TachoSil\            30\          5.87±1.07\             *P*=0.01
                                                                                                                                               Standard technique   30           7.50±3.20              

  Anegg et al[@b22-vhrm-10-569]        2008   Germany, Austria                             Randomized clinical trial   Lung                    TachoSil\            75\          6.20\                  *P*=0.01
                                                                                                                                               Standard technique   77           7.7                    

  Droghetti et al[@b23-vhrm-10-569]    2008   Italy                                        Randomized clinical trial   Lung                    TachoSil\            20\          11.00 (9--17)\         *P*=0.73
                                                                                                                                               Standard technique   20           14.3 (8--57)           

  Onorati et al[@b31-vhrm-10-569]      2008   Italy                                        Prospective cohort          Cardiac                 TachoSil\            11\          6.2±0.4\               *P*=0.01
                                                                                                                                               Standard technique   18           8.9±3.3                

  Barranger et al[@b32-vhrm-10-569]    2007   France                                       Prospective cohort          Breast                  TachoSil\            13\          3.5\                   ns
                                                                                                                                               Standard technique   12           5.5                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** ns, no statistically significant difference.

###### 

Reduction in postoperative complications: TachoSil versus other standard techniques

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                       Year   Countries                                   Design                      Surgery                            Sealing agents       Patient no   Postoperative complications                      Statistical difference (*P*-value)
  -------------------------------------------- ------ ------------------------------------------- --------------------------- ---------------------------------- -------------------- ------------ ------------------------------------------------ ------------------------------------
  **Air leaks (lung surgery)**                                                                                                                                                                                                                      

  Filosso et al[@b18-vhrm-10-569]              2013   Italy                                       Randomized clinical trial   Lung                               TachoSil\            13\          4.7/days air leaks\                              *P*\<0.001
                                                                                                                                                                 Standard technique   11           10/days                                          

  Marta et al[@b21-vhrm-10-569]                2010   Germany, Austria, Denmark, Hungary, Italy   Randomized clinical trial   Lung                               TachoSil\            148\         Global: 32%\                                     *P*=0.022
                                                                                                                                                                 Standard technique   151          Global: 58%                                      

  Rena et al[@b30-vhrm-10-569]                 2009   Italy                                       Prospective cohort                                             TachoSil\            30\          Global: 55%\                                     *P*=0.03
                                                                                                                                                                 Standard technique   30           Global: 96%                                      

  Anegg et al[@b22-vhrm-10-569]                2008   Austria, Germany                            Randomized clinical trial   Lung                               TachoSil\            75\          Day 1: 43.6 mL/minutes\                          *P*=0.004
                                                                                                                                                                 Standard technique   77           Day 1: 86.1mL/minutes                            

  Droghetti et al[@b23-vhrm-10-569]            2008   Italy                                       Randomized clinical trial   Lung                               TachoSil\            20\          Global: 50%\                                     *P*=0.001
                                                                                                                                                                 Standard technique   20           Global: 95%                                      

  **Intra-abdominal infections**                                                                                                                                                                                                                    

  Padillo et al[@b29-vhrm-10-569]              2010   Spain                                       Prospective cohort          Pancreatic transplant              TachoSil\            34\          0%\                                              *P*=0.003
                                                                                                                                                                 Standard technique   34           32%                                              

  **Development of asymptomatic lymphocele**                                                                                                                                                                                                        

  Simonato et al[@b33-vhrm-10-569]             2009   Italy                                       Randomized clinical trial   Prostate                           TachoSil\            30\          5%\                                              *P*=0.001
                                                                                                                                                                 Standard technique   30           19%                                              

  **Pericardial complications**                                                                                                                                                                                                                     

  Onorati et al[@b31-vhrm-10-569]              2008   Italy                                       Prospective cohort          Cardiac                            TachoSil\            11\          0%\                                              *P*=0.039
                                                                                                                                                                 Standard technique   18           33%                                              

  **Postoperative fistulas**                                                                                                                                                                                                                        

  Montorsi et al[@b19-vhrm-10-569]             2012   Italy                                       Randomized clinical trial   Pancreatic                         TachoSil\            145\         62.00%\                                          *P*=0.267
                                                                                                                                                                 Standard technique   130          68.00%                                           

  Pavlik et al[@b26-vhrm-10-569]               2011   Norway                                      Retrospective cohort        Pancreatic resection               TachoSil\            73\          8.00%\                                           *P*=0.487
                                                                                                                                                                 Standard technique   48           12.00%                                           

  **Other complications**                                                                                                                                                                                                                           

  Kakaei et al[@b12-vhrm-10-569]               2013   Iran                                        Randomized clinical trial   Hepatic                            TachoSil\            15\          Postoperative bleeding: 0\                       *P*=0.04
                                                                                                                                                                 Surgicel\            15\          Postoperative bleeding: 33%\                     
                                                                                                                                                                 Glubran 2            15           Postoperative bleeding: 13.3%                    

  Cormio et al[@b24-vhrm-10-569]               2012   Italy                                       Randomized clinical trial   Kidney                             TachoSil\            50\          Tract complication: 2%\                          *P*\<0.001
                                                                                                                                                                 Standard technique   50           Tract complication: 25.5%                        

  Buda et al[@b34-vhrm-10-569]                 2012   Italy                                       Case-controlled analysis    Vulvar/ovarian and breast cancer   TachoSil\            8\           Lower drainage volume: 133 mL\                   *P*\<0.001
                                                                                                                                                                 Standard technique   16           Lower drainage volume: 320 mL                    

  Briceno et al[@b28-vhrm-10-569]              2010   Spain                                       Prospective cohort          Hepatic                            TachoSil\            57\          Postoperative complications: 8%\                 *P*=0.03
                                                                                                                                                                 Standard technique   58           Postoperative complications: 21%                 

  Tamasauskas et al[@b35-vhrm-10-569]          2008   Lithuania                                   Prospective cohort          Neurosurgery                       TachoSil\            29\          Postoperative cerebrospinal fluid leak: 13.8%\   *P*=0.02
                                                                                                                                                                 Standard technique   29           Postoperative cerebrospinal fluid leak: 41.4%    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
